Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123916 | 0.81 | EPHX1 (0.48) | ANPEPTAAR1CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL3129213 | 0.81 | EPHX1 (0.48) | ANPEPTAAR1CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL1818191 | 0.80 | ANPEP (0.43) | ANPEPERAP1ERAP2TAAR1CYP2A6 | |
| SCHEMBL4608897 | 0.80 | ANPEP (0.43) | ANPEPERAP1ERAP2TAAR1CYP2A6 | |
| SCHEMBL17604782 | 0.76 | ANPEP (0.46) | ANPEPERAP1ERAP2TAAR1CYP2A6 | |
| SCHEMBL3133675 | 0.75 | TACR1 (0.49) | TAAR1 | |
| Hydrochloric Acid SCHEMBL7303614 | 0.74 | ANPEP (0.44) | ANPEPERAP1ERAP2TAAR1CYP2A6 | |
| SCHEMBL6551164 | 0.73 | SLC18A2 (0.46) | ANPEPERAP1ERAP2 | |
| SCHEMBL7785415 | 0.73 | SLC18A2 (0.46) | ANPEPERAP1ERAP2 | |
| SCHEMBL9390743 | 0.73 | ALDH1A1 (0.44) | ANPEPERAP1ERAP2TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491537-B1 | HYDROXYMORPHOLINONE DERIVATIVE AND MEDICINAL USE THEREOF | SENJU PHARMA CO (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | ANPEP 974/4885ERAP1 291/4885ERAP2 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.